Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03169881 · ClinicalTrials.gov registry record · Phase 3
Darbepoetin Trial to Improve Red Cell Mass and Neuroprotection in Preterm Infants
A Phase 3 study, sponsored by NICHD Neonatal Research Network.
- Completed
- Registry status
- Phase 3
- Development phase
- 650
- Enrollment target
NCT03169881 is a Phase 3 study that has completed, run by NICHD Neonatal Research Network. The registered enrollment target is 650 participants.
The verdict
NCT03169881, a Phase 3 study, has completed, sponsored by NICHD Neonatal Research Network.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 650 participants
- Enrollment target
Study Summary
Study Hypothesis: Preterm infants administered weekly Darbe during the neonatal period will have improved neurocognitive outcome at 22-26 months compared to placebo
Interventions
- DRUG Placebo
- DRUG Darbepoetin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 650 participants |
| Start Date | 2017-09-20 |
| Est. Completion | 2025-05-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03169881
The ClinicalTrials.gov registry entry for NCT03169881 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 650 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NICHD Neonatal Research Network, which has 61 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03169881 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03169881 about?
NCT03169881 is a clinical study titled "Darbepoetin Trial to Improve Red Cell Mass and Neuroprotection in Preterm Infants". Study Hypothesis: Preterm infants administered weekly Darbe during the neonatal period will have improved neurocognitive outcome at 22-26 months compared to placebo
What is the current status of trial NCT03169881?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 650 participants. The study started on 2017-09-20. Estimated completion is 2025-05-12.
What interventions are being tested in trial NCT03169881?
The interventions under investigation include: Placebo (DRUG), Darbepoetin (DRUG).
Who is sponsoring clinical trial NCT03169881?
This trial is sponsored by NICHD Neonatal Research Network, which has 61 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.